Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.

Subjects

Abstract

Risk stratification of patients with acute myocardial infarction (AMI) is of clinical significance. Although there are many existing risk scores, periodic update is required to reflect contemporary patient profile and management. The present study aims to develop a risk model to predict in-hospital death among contemporary AMI patients as soon as possible after admission. We included 23417 AMI patients from China Acute Myocardial Infarction (CAMI) registry from January 2013 to September 2014 and extracted relevant data. Patients were divided chronologically into a derivation cohort (n = 17563) to establish the multivariable logistic regression model and a validation cohort (n = 5854) to validate the risk score. Sixteen variables were identified as independent predictors of in-hospital death and were used to establish CAMI risk model and score: age, gender, body mass index, systolic blood pressure, heart rate, creatinine level, white blood cell count, serum potassium, serum sodium, ST-segment elevation on ECG, anterior wall involvement, cardiac arrest, Killip classification, medical history of hypertension, medical history of hyperlipidemia and smoking status. Area under curve value of CAMI risk model was 0.83 within the derivation cohort and 0.84 within the validation cohort. We developed and validated a risk score to predict in-hospital death risk among contemporary AMI patients.

Introduction

Ischemic heart disease has become the leading contributor of disease burden worldwide1. Acute myocardial infarction (AMI) is the most severe manifestation of ischemic heart disease. In the United States, approximately 750000 individuals suffer from first or recurrent MI every year2. In Europe, the 30-day case-fatality rate ranged from 4.5% in Sweden and 15.4%in Latvia3. In China, an increase in AMI mortality rate was observed and the rate was over 50 per 100000 population in 20144.

Considerable variability exists among patients with AMI and many factors have an impact on an individual’s prognosis. Careful risk stratification is of clinical significance, as it informs decisions regarding treatment strategies as well as triage among alternative levels of care and provides an opportunity to estimate patient’s prognosis. Guidelines from both the American College of Cardiology/American Heart Association2,5 and the European Society of Cardiology6 recommended that the most appropriate pharmacological and interventional management should be determined after comprehensive risk assessment.

Many risk models of in-hospital mortality have been developed among patients with acute coronary syndrome7,8,9,10,11. Among these scores, The Thrombolysis in Myocardial Infarction(TIMI) score and the Global Registry in Acute Coronary Events (GRACE) score are the most commonly used and are recommended in the guideline6. However, both scores were developed when patient characteristics and management differed significantly from now, and few participants were from Asia. Therefore, it is necessary to update the existing models and the purpose of our study is to develop a multivariable logistic regression model to predict in-hospital mortality risk among patients with AMI.

Methods

CAMI registry

Details of China AMI (CAMI) registry design and method were described previously12. Briefly, CAMI registry was a prospective, multicenter observational registry conducted in China, which included patients with AMI and collected data on patients’ demographics, clinical presentation, initial medical contact, medical history and risk factors, treatment and clinical outcomes. Data were collected at each participating site by trained clinical cardiologists using electronic clinical reporting form. A total of 108 hospitals with different levels covering a broad geographic region participated in the project, which assured a good representation of AMI patients from China. The CAMI registry was registered on www.Clinicaltrials.gov (registration number: NCT01874691).

Our study was approved by the institutional review board central committee at Fuwai Hospital, NCCD of China. Written informed consent was obtained from eligible patients before registration. We confirmed that all methods were performed in accordance with the relevant guidelines.

Study population

All patients enrolled in CAMI registry were included in our study. Eligible patients were diagnosed with AMI including ST-segment elevation myocardial infarction (STEMI) and non–ST elevation myocardial infarction (NSTEMI) in accordance with the third universal definition of myocardial infarction13. AMI classified as type 1, 2, 3, 4b and 4c were included in CAMI registry12. Type 4a and type 5 were not eligible for the CAMI registry. We excluded those patients with missing or invalid data on age, BMI, admission diagnosis and in-hospital outcome.

Outcome measurement and clinical definition

The primary endpoint was all-cause in-hospital death defined as cardiac or non-cardiac death during hospitalization. Medical history and vital signs were determined at the time of first hospital presentation. Standard definition of the history and physical examination elements were well described in the ACC/AHA Task Force on clinical Data Standards and NCDR-ACTION-GWTG element dictionary. ECG and echocardiogram were interpreted locally.

Statistical analysis

Baseline continuous variables were presented as mean ± SD or median (25th and 75th percentiles), and categorical variables were presented as counts and percentages. We used Student t tests to compare the continuous variables between in-hospital deaths and survivors, and chi-square tests to compare categorical variables. Univariate logistic regression was performed to examine the association between individual baseline variable and in-hospital mortality, which was described as odds ratio (OR) and 95% confidence interval (CI). All variables that achieved a significance level of P ≤ 0.25 were selected to fit the multivariable logistic regression model. Stepwise selection process was used to identify independent predictors of in-hospital death.

After selection, those variables with P < 0.05 were retained in the final model. A simplified risk score was developed for clinical practice by attributing integer numbers to these variables. The variable with the smallest estimated coefficient (reference variable) was attributed 1 point. The scores of other variables were determined by dividing their estimated coefficients by the coefficient of the reference variable14. We used area under curve (AUC) value and Hosmer-Lemeshow (HL) goodness-of-fit test to assess discrimination and calibrationability of the model respectively.

Data availability statement

The data used in our study was from CAMI registry dataset and is not publicly available but is available from corresponding author on reasonable request.

Results

Baseline characteristics

From January 1st 2013 to September 30th 2014, a total of 26036 patients were enrolled in CAMI registry. We excluded 2619 patients with incomplete data on age, BMI, diagnosis on admission, in-hospital outcome and finally included 23417 patients in our study. There were 1504 (6.4%) patients died in the study sample (Fig. 1). Baseline characteristics are shown in Table 1. Compared with survivors, patients who died were older, more often female and had higher BMI. Proportion of cardiac arrest and higher Killip classification were higher among deaths vs. survivors. Patients who died also had more comorbidities.

Figure 1

Study flow chart. From January 2013 to September 2014, a total of 26036 patients were enrolled in CAMI registry. After excluding 2619 patients due to critical data missing, we finally included 23417 AMI patients. A total of 1504 patients died during hospitalization.

We included 5795 patients with NSTEMI and 17622 patients with STEMI in our study. Among patients with NSTEMI, 541 (9.3%) patients received early invasive approach. Among patients with STEMI, 7587 (43.0%) patients were treated with primary PCI, and 1739 (9.9%) patients received thrombolytic therapy.

CAMI risk score

We developed a simplified risk score by attributing integer number to each variable according to their estimated coefficients (Table 4). Corresponding in-hospital mortality risk associated with each point is shown in supplementary Table 1. CAMI risk score ranges from 0 to 284, and corresponding in-hospital death risk ranges from 0.3% to 97.7%. Within derivation cohort, area under curve value for CAMI risk model was 0.83 (95% CI: 0.82-0.84). AUC value for the simplified CAMI risk score was only slightly worse than that of CAMI risk model (0.83 vs. 0.80, p = 0.07) (Fig. 2). Hosmer-Lemeshow P (HL-P) value for CAMI risk score was 0.10, which indicated good calibration. Within validation cohort, AUC value for CAMI risk model and score were 0.84 (95% CI: 0.82-0.86) and 0.80 (95% CI: 0.78-0.83), and no significant difference in AUC value was detected (P = 0.07) (Fig. 3).

We compared the diagnostic performance of CAMI risk score with GRACE risk score. The AUC value for CAMI score and GRACE risk score was 0.8043 and 0.8054 respectively (p = 0.8 for comparison). We also demonstrated that the diagnostic performance of CAMI risk score was superior to that of TIMI risk score (C-statistics: 0.8043 for CAMI and 0.7781 for TIMI risk score, p < 0.0001 for comparision).

Within derivation cohort, we divided all participants into three groups (Tertile I, II, III) based on tertiles. Each tertile contained approximately one third of the population (Table 5). Event rate increased significantly across tertiles: 1.12% in Tertile I (score range: 0–93), 3.47% in Tertile II (score range: 94–117), 14.70% in Tertile III (score range: ≥118). Within validation cohort, a similar pattern was observed and event rate also increased significantly across tertiles: 0.79% in Tertile I, 3.24% in Tertile II and 13.66% in Tertile III. Therefore, we defined Tertile I, II, III as low, intermediate and high risk group respectively.

Discussion

In a large-scale contemporary prospective registry of patients with AMI in China, we identified 16 independent predictors of in-hospital deaths, and by using these variables, we developed and validated a risk prediction tool of in-hospital death among AMI patients. CAMI risk score had high discrimination and calibration ability in both the derivation and validation cohort. A significant gradient of in-hospital mortality risk was identified with increased CAMI score.

Comparison with GRACE

Many risk prediction tools have been developed to assess short- or long-term mortality risk of ACS patients, among which GRACE and TIMI risk score were the most popular and validated tool. We demonstrated that CAMI risk score was non-inferior to GRACE and was superior to TIMI risk score in terms of c-statistics. In this part, we focused our comparison with GRACE risk score because CAMI score shared similar study design with GRACE score (GRACE score was designed from registry data while TIMI score was derived from clinical trial data).

Since the creation of GRACE risk score, patient profile of AMI has changed over time, with a slight increase in NSTEMI and a decrease in STEMI, and an overall decline in AMI15. Updated diagnostic criteria of AMI also have an impact on the detection and prevalence of AMI. For instance, the introduction of troponin, a relatively new biomarker, into AMI definition was reported to lead to increased annual incidence rate16. A proportion of unstable angina (UA) patients will be diagnosed as MI in the era of high-sensitive troponin, leading to an increase in MI and a reciprocal decrease in UA6. Due to improvement in medication and invasive treatment, in-hospital mortality of STEMI has declined significantly17. These changes require periodic updates of existing models, which justifies our work.

Although GRACE registry was a large-scale multinational registry enrolling patients from 14 countries in North America, South America, Europe, Australia, and New Zealand, few participants were from Asia18. However, including participants from Asia is of great clinical significance: The population of Asia is greater than 4.2 million, which accounts for around 60% world population19. ACS is the leading cause of mortality in Asia and is estimated to account for half of the global burden20. Our work bridged the evidence gap, developed and validated a novel risk model by using data from CAMI registry, the largest prospective multicenter registry of patients with AMI in Asia region.

Variables in the model

Many variables in CAMI risk model were identical to those in GRACE risk score including: age, SBP, creatinine, ST-segment elevation, cardiac arrest, Killip classification, hypertension, anterior wall involvement. Novel variables in our score included: hyperlipidemia, gender, BMI and smoking. Unexpectedly, hyperlipidemia was a protective factor of in-hospital death. This may be explained by the fact that patients with hyperlipidemia are more likely to take lipid-lowering medications including statins, and there is a significant increase trend in statins use over decades21, which maybe associated with improved prognosis. Our study found that female gender was an independent risk factor of in-hospital death, while in GRACE risk score, gender was not associated with mortality risk in multivariable analysis. This discrepancy maybe caused by difference in study population. Approximately one third participants in GRACE registry were diagnosed with UA22, while we did not include UA patients. Compared with MI, patients with UA were more often females, and had lower death risk since they do not have myocardial necrosis. These factors can have an impact on the association between gender and mortality6.

Our study demonstrated the phenomenon of smoker’s and obesity paradox. Although smoking and obesity are well established risk factors of coronary artery disease, current smokers (compared with nonsmokers) and patients with high BMI (compared with patients with low BMI) paradoxically had lower in-hospital mortality. Possible explanations for smoker’s paradox were difference in fibrinolytic therapy effectiveness among smokers vs. nonsmokers. Smokers had increased level of circulating fibrinogen and more fibrin-rich thrombus compared with nonsmokers. Therefore, smokers may have improved myocardial perfusion and prognosis after fibrinolysis treatment23. The phenomenon of obesity paradox had been found in cases of several heart conditions including acute myocardial infarction, hypertension, heart failure, atrial fibrillation24. Several mechanisms have been proposed to explain obesity paradox: Obese individuals may have higher energy reserve in response to acute stress25, and more likely to receive optimal medication therapy and invasive treatment26. Of note, we included smoking status and BMI in CAMI risk score to improve the diagnostic performance of the risk model, and should not interpreted as the encouragement of smoking or obesity.

Limitations

First, CAMI risk score should be further validated in separate large-scale cohort. Second, all participants were from China, whether CAMI score can be applied to other ethnicities need further validation. CAMI score was designed for rapid risk assessment after presentation, so we didn’t include some laboratory test variables such as troponin level and left ventricular ejection fraction.

Conclusions

Using data from a large-scale contemporary cohort, we developed and validated a risk score to accurately predict risk of in-hospital death risk among patients with AMI. CAMI risk score had high discrimination and calibration ability and is likely to be useful for clinicians to assess in-hospital death risk accurately and to select optimal management.

Acknowledgements

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-1–009), Twelfth Five-Year Planning Project of the Scientific and Technological Department of China (2011BAI11B02) and 2014 Special fund for scientific research in the public interest by National Health and Family Planning Commission of the People’s Republic of China (No. 201402001). We are grateful for all participants in CAMI study group for their hard work and active participation. We are very grateful to the TIMI Study Group and the Duke Clinical Research Institute for their contributions in the design, conduct, and data analyses of CAMI registry.

Contributions

Kefei Dou and Yuejin Yang contributed equally to conception and design of the study. Both of them are corresponding authors. Chenxi Song and Rui Fu contributed equally in writing the manuscript. Jingang Yang, Haiyan Xu, Xiaojin Gao, Guofeng Gao, Zhiyong Zhao revised it critically for important intellectual content. Wei Li and Jia Liu contributed to analysis and interpretation of data.

Additional information

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.